Terms: = Colorectal cancer AND SMAD2, MADH2, 4087, ENSG00000175387, MGC34440, MGC22139, hMAD-2, MADR2, JV18-1, hSMAD2, JV18 AND Clinical Outcome
4 results:
1. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
Miyamoto Y; Schirripa M; Suenaga M; Cao S; Zhang W; Okazaki S; Berger MD; Matsusaka S; Yang D; Ning Y; Baba H; Loupakis F; Lonardi S; Pietrantonio F; Borelli B; Cremolini C; Yamaguchi T; Lenz HJ
PLoS One; 2020; 15(9):e0239439. PubMed ID: 32970737
[TBL] [Abstract] [Full Text] [Related]
2. Significance of positive and inhibitory regulators in the TGF-β signaling pathway in colorectal cancers.
Coates RF; Gardner JA; Gao Y; Cortright VM; Mitchell JM; Ashikaga T; Skelly J; Yang MX
Hum Pathol; 2017 Aug; 66():34-39. PubMed ID: 28601657
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer.
Storojeva I; Boulay JL; Ballabeni P; Buess M; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncology; 2005; 68(2-3):246-55. PubMed ID: 16015041
[TBL] [Abstract] [Full Text] [Related]
4. Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis.
Xie W; Rimm DL; Lin Y; Shih WJ; Reiss M
Cancer J; 2003; 9(4):302-12. PubMed ID: 12967141
[TBL] [Abstract] [Full Text] [Related]
